3 July 2025 The architect of an historic change in the way patent claims are interpreted explains what it means for AI drafting, and why more harmonisation may follow, reports Tom Phillips
1 July 2025
Latest Features
Europe
Despite efforts to harmonise, the Unified Patent Court’s local divisions and Court of Appeal have signalled a divergence over implementing the European Patent Convention—but does it matter? Chris Moore and Hsu Min Chung of HGF report.
Europe
Two years since the UPC opened its doors, various developments might influence the UK government to reassess its position, write Amanda Ebbutt and Paul England of Taylor Wessing.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Africa
Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.
Europe
Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo.
Unified Patent Court
The UPC Court of Appeal’s approach to delivering a preliminary injunction in a glucose sensor dispute has far-reaching effects, as Wouter Pors of Bird & Bird explains.
More News
30 June 2025 This session brings together experts from Choate, Radius Health, and Syros Pharmaceuticals to examine the current policy landscape affecting life sciences patents. Discussions focus on recent developments such as the Inflation Reduction Act’s drug pricing provisions and concerns over patent examination quality at the USPTO.
26 June 2025 Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major changes to European law | Case returns to lower court for novelty and inventive step evaluation.
26 June 2025 Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly delaying market entry of generic Pomalyst | Lawsuit follows dismissal of antitrust suit against pharma giant over same drug.
25 June 2025 This panel brings together experts from Wolf Greenfield, BlueRock Therapeutics, BioNTech, and Generate Biomedicines to explore the evolving landscape of pharmaceutical collaborations. The discussion focuses on how partnerships can accelerate drug discovery, share risks, and pool resources in today’s complex drug development environment.
24 June 2025 Trio have worked together for several years at different firms, bringing decades of experience in medical devices, robotics, and life sciences.
24 June 2025 AstraZeneca and Kudos must disclose alternative deal structures by October 2025 | Ruling aims to clarify counterfactual damages defence ahead of expert meetings.
24 June 2025 Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox